Browsing Tag
Christopher Viehbacher
1 post
Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in…